Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Penpulimab Combined With Chemotherapy for Neoadjuvant and Adjuvant Therapy in Resectable Head and Neck Squamous Cell Carcinoma
NCT06081673Phase 2Active, not recruiting
- Sponsor
- Shanghai Ninth People's Hospital
- Start
- Oct 2023
- Primary completion
- Dec 2026
- Modality
- Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
A Phase 2 trial of penpulimab in head and neck squamous cell carcinoma (HNSCC), sponsored by Shanghai Ninth People's Hospital. Started Oct 2023; status: active, not recruiting.
02
Drugs
penpulimab
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT06081673.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06081673.